Ophirex
Corte Madera
About Ophirex
Ophirex, is developing a first in class drug that will help the 500,000 people who die or suffer amputations each year from venomous snakebite. 70% of those who die never even make it to the hospital for treatment. Because Ophirex's drug will be available in an oral formulation, all that will change. Our drug is a small molecule inhibitor that targets the most lethal component of venom, so it will be effective against the most dangerous snakes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $53.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2023)
- Website: ophirex.com
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ophirex-95606 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.